<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77645</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli</dc:title>
<dc:description xml:lang="en">The aim of this job is to study the capacity of ciprofloxacinand levofloxacin in restricting the developmentof resistant mutants in strains of Escherichia coli by determiningthe mutant prevention concentration (MPC). Ninety-nine isolates of E. coli with different fluoroquinolonesusceptibilities were studied and divided intoESBL-producing (n = 60) and non-ESBL producing(n=36) groups. MPC values were determined using aninoculum of 1010 cfu/ml on Mueller-Hinton plates withserial dilutions of the antibiotics. No significative differenceswere detected in MIC of ESBL-producing andnon-ESBL producing strains of E. coli. Ciprofloxacinsusceptible ESBL-producing strains exhibit higher MPCfor ciprofloxacin and levofloxacin than non-ESBL producingstrains. Our study helps to explain the frequentfluoroquinolone resistance found in ESBL-producingstrains. In this context, doubts emerge about the advisabilityof using fluoroquinolones to treat infections causedby ESBL-producing strains (AU)</dc:description>
<dc:creator>Ruiz, M</dc:creator>
<dc:creator>Rodríguez, J. C</dc:creator>
<dc:creator>Royo, G</dc:creator>
<dc:creator>López, J. M</dc:creator>
<dc:creator>Noguera, O</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El objetivo de este trabajo es estudiar la capacidad de ciprofloxacinoy levofloxacino de restringir el desarrollo demutantes resistentes en cepas de Escherichia coli mediantela determinación de la concentración preventiva de mutantes(CPM). Se estudiaron 99 cepas de E. coli con distinta sensibilidada fluoroquinolonas y se clasificaron en cepas productoras(n=60) y no productoras (n=39) de betalactamasasde espectro extendido (BLEE). La determinación de la CPM serealizó mediante el inóculo de 1010 UFC/ml en placas deMueller-Hinton con concentraciones seriadas de antibióticos.No se detectaron diferencias significativas entre lasconcentraciones inhibitorias mínimas de cepas productorasy no productoras de BLEE. Las cepas sensibles a ciprofloxacinoy productoras de BLEE mostraron una mayor CPM paralevofloxacino y ciprofloxacino que las no productoras.Nuestro estudio ayuda a explicar el frecuente hallazgo deresistencias a fluoroquinolonas en cepas productoras deBLEE. En este contexto surgen dudas sobre la convenienciade usar fluoroquinolonas en el tratamiento de infeccionescausadas por cepas productoras de BLEE (AU)</dc:description>
<dc:source>Rev Esp Quimioter;22(1): 30-33, mar. 2009. tab, graf</dc:source>
<dc:identifier>ibc-77645</dc:identifier>
<dc:title xml:lang="es">Determinación de la concentración preventiva de mutantes resistentes a fluoroquinolonas en aislamientos clínicos de Escherichia coli productoras y no productoras de betalactamasas de espectro extendido</dc:title>
<dc:subject>^d22165^s22038</dc:subject>
<dc:subject>^d5016^s22021</dc:subject>
<dc:subject>^d5016^s22031</dc:subject>
<dc:subject>^d5016^s22052</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d24244^s22083</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24244^s22074</dc:subject>
<dc:subject>^d36060^s22079</dc:subject>
<dc:subject>^d24244^s22066</dc:subject>
<dc:subject>^d36060^s22000</dc:subject>
<dc:subject>^d24244^s22039</dc:subject>
<dc:subject>^d36060^s22073</dc:subject>
<dc:subject>^d38654^s22078</dc:subject>
<dc:subject>^d38654^s22079</dc:subject>
<dc:type>article</dc:type>
<dc:date>200903</dc:date>
</metadata>
</record>
</ibecs-document>
